We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

288 hedge funds and large institutions have $5.34B invested in Intra-Cellular Therapies Inc. in 2023 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 115 increasing their positions, 78 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more call options, than puts

Call options by funds: $16.6M | Put options by funds: $10.7M

47% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 78

42% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 36

38% more funds holding in top 10

Funds holding in top 10: 8 → 11 (+3)

18% more capital invested

Capital invested by funds: $4.55B → $5.34B (+$797M)

5% more funds holding

Funds holding: 274 → 288 (+14)

Holders
288
Holders Change
+14
Holders Change %
+5.11%
% of All Funds
4.52%
Holding in Top 10
11
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+37.5%
% of All Funds
0.17%
New
51
Increased
115
Reduced
78
Closed
36
Calls
$16.6M
Puts
$10.7M
Net Calls
+$5.94M
Net Calls Change
-$34M

Top Buyers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$36.7M
2
Holocene Advisors
Holocene Advisors
New York
+$36.1M
3
Macquarie Group
Macquarie Group
Australia
+$35.4M
4
NIP
Nicholas Investment Partners
California
+$31.1M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$30.5M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$207M
2
WA
Wasatch Advisors
Utah
-$62M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$47.1M
4
DM
Deerfield Management
New York
-$39.7M
5
Citadel Advisors
Citadel Advisors
Florida
-$36.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
FHB
201
First Hawaiian Bank
Hawaii
$436K – – –
GCP
202
GSA Capital Partners
United Kingdom
$427K +$421K +6,751 New
SEC
203
Seven Eight Capital
New York
$419K -$438K -7,030 -51%
JIP
204
Jaffetilchin Investment Partners
Florida
$414K -$11.8K -190 -3%
VHAM
205
Van Hulzen Asset Management
California
$380K -$24.9K -400 -6%
GAM
206
Gemmer Asset Management
California
$380K -$125K -2,000 -25%
Neuberger Berman Group
207
Neuberger Berman Group
New York
$371K +$28.3K +454 +8%
TRSOTSOK
208
Teachers Retirement System of the State of Kentucky
Kentucky
$355K -$1.05M -16,923 -75%
X
209
Xponance
Pennsylvania
$347K -$10.7K -172 -3%
VEA
210
Virtus ETF Advisers
New York
$338K -$31.4K -504 -9%
M&T Bank
211
M&T Bank
New York
$327K -$29.2K -469 -8%
MLICM
212
Metropolitan Life Insurance Company (MetLife)
New York
$324K +$10.9K +175 +4%
DTL
213
Dynamic Technology Lab
Singapore
$318K +$313K +5,020 New
II
214
Inspire Investing
Idaho
$317K +$872 +14 +0.3%
SLT
215
St Louis Trust
Missouri
$317K – – –
Rafferty Asset Management
216
Rafferty Asset Management
New York
$307K +$33.8K +543 +13%
AI
217
AdvisorShares Investments
Maryland
$299K -$7.17K -115 -2%
UB
218
UMB Bank
Missouri
$295K – – –
PI
219
PFG Investments
New York
$279K -$18.7K -300 -6%
Creative Planning
220
Creative Planning
Kansas
$277K +$273K +4,381 New
AI
221
Atom Investors
Texas
$261K +$257K +4,117 New
Allspring Global Investments
222
Allspring Global Investments
North Carolina
$257K -$213K -3,424 -46%
Osaic Holdings
223
Osaic Holdings
Arizona
$254K +$28.7K +461 +13%
AWCI
224
Alpine Woods Capital Investors
New York
$253K – – –
RFC
225
Regions Financial Corp
Alabama
$249K +$7.67K +123 +3%
7 8
9
10 11

ITCI Hedge Fund Activity: Q2 2023 in Review

288 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2023, worth a combined $5.34B — up 18% from $4.55B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new ITCI positions and 36 closed out — a net gain of 15 holders — while 115 added to existing stakes and 78 trimmed.

The largest buyer was Lord, Abbett & Co, adding an estimated $36.7M. The largest seller was Wellington Management Group, cutting an estimated $207M.

  • 288 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2023, up from 274 in Q1 2023.
  • Funds reported $5.34B of Intra-Cellular Therapies Inc. stock for Q2 2023, up 18% quarter-over-quarter.
  • 51 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2023 and 36 closed out, a net change of +15 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2023 was Lord, Abbett & Co, an estimated $36.7M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2023 was Wellington Management Group, an estimated $207M sold.

Based on aggregated 13F filings for Q2 2023.